•  

Toronto Innovation Acceleration Partners – TIAP – specializes in  venture building of

early-stage health science technologies emerging from our members.

TIAP was formerly MaRS Innovation

Our Members
TIAP’s portfolio draws from three universities, nine teaching hospitals and two research institutes. Learn more about our members.
Learn More›
Work With Us
Through our member-exclusive funding programs and services, TIAP works with founders to bring their health science technologies to market faster.
Learn More›
Recent News

Allogene Therapeutics enters collaboration with Notch Therapeutics

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on …

Notch Therapeutics, a new company in the field of gene-modified T cell therapy

Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) — Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited …

Zealand Pharma Acquires Encycle Therapeutics

Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a …

TIAP shifted my perspective from BlueDot's research to its potential as a global business. They worked with me to incorporate the company, develop a business plan and model suitable for a social enterprise, and hire key talent, while supporting me through BlueDot’s early stages of growth and development.
Kamran Khan, MD, MPH
Founder / BlueDot
TIAP understood the value of my invention and saw its potential when others didn’t (they’re starting to now!). I’m grateful for the investment and mentoring I received through the UTEST program.
James Colliander, PhD
Co-Founder / Crowdmark
The UTEST program and TIAP have been fantastic for TrendMD; we would not be where we are today without them. Both from a strategic and financial perspective, UTEST definitely served as the initial spark that was crucial for getting us off the ground.
Paul Kudlow, MD
Founder / TrendMD
TIAP’s unique ecosystem allows innovators and researchers to keep the high impact of their innovation while enabling it with frameworks for commercialization. Their dedicated expert team allowed us to launch, structure and scale our company both in Canada and in the rest of the world while allowing us to maintain our research and academic mandates.
Hossein Rahnama, PhD
Founder / Flybits
TIAP was a vital partner as we refined our technology, our business model and our go-to-market strategy. Without their support, and the support of UTEST, we would not be in the position we are today.
Craig Boutilier, PhD
Co-Founder / Granata Decision Systems